Histology of Cardiac Tissue

Cardiomyocyte Structure and Organization

• Z-discs (Z-lines): Dense protein structures composed primarily of α-actinin that anchor thin filaments and demarcate sarcomere boundaries; connect adjacent sarcomeres longitudinally and link to the lateral membrane via costameres
• Sarcomere: The contractile unit extending from Z-disc to Z-disc, containing thick filaments (myosin), thin filaments (actin, tropomyosin, troponin), and regulatory proteins; length changes from ~2.2 μm (relaxed) to ~1.6 μm (contracted)
• Intercalated discs: Specialized junctions at cardiomyocyte boundaries containing desmosomes (mechanical adhesion via desmoplakin, desmoglein, desmocollin), gap junctions (electrical coupling via connexin-43), and adherens junctions (via N-cadherin, β-catenin, α-catenin); mutations cause arrhythmogenic cardiomyopathy

Myofilament Architecture

• Thick filaments: ~1.6 μm length composed of myosin II (heavy and light chains) with regular cross-bridges every 14.3 nm; powered myosin heads hydrolyze ATP and interact with thin filaments
• Thin filaments: ~1.0 μm length containing F-actin, tropomyosin (covers myosin-binding sites in resting state), and troponin complex (troponin I, C, T); troponin C binds calcium triggering tropomyosin conformational change
• Regulatory proteins: Titin (giant elastic protein spanning half-sarcomere, providing passive tension and stabilizing thick filaments), nebulin (guides actin filament length), myomesin (M-line protein linking thick filaments)

Subcellular Organization and Energy Metabolism

• Mitochondria: Account for 30-40% of cardiomyocyte volume (highest in ventricles); densely packed around myofibrils and beneath sarcolemma; ATP production via oxidative phosphorylation sustains continuous contraction
• Sarcoplasmic reticulum (SR): Specialized endoplasmic reticulum storing calcium; ryanodine receptors (RyR2) release calcium during excitation-contraction coupling; SERCA2a pumps reuptake calcium consuming ATP
• T-tubules: Invaginations of sarcolemma at Z-disc level forming dyads with SR; conduct action potentials deep into cell and synchronize calcium release across myofibril

Conducting Tissue Architecture

• Sinoatrial (SA) node: Modified cardiomyocytes lacking organized myofilaments; pacemaker cells demonstrate automaticity via funny current (HCN4) and calcium oscillations; located at junction of superior vena cava and right atrium
• Atrioventricular (AV) node: Compact nodal tissue with small diameter fibers, increased intercellular connective tissue, fewer gap junctions (delayed conduction); located in triangle of Koch between coronary sinus and septal leaflet
• Purkinje fibers: Large-diameter, low-resistance conducting fibers in subendocardium; high velocity conduction (2-4 m/s); rich in glycogen, minimal myofibrils; allow rapid coordinated ventricular depolarization

Fibrous Skeleton and Support Architecture

• Cardiac fibrous skeleton: Dense collagenous framework surrounding valves, annuli, and atrial-ventricular junction; provides mechanical support, electrical insulation between atria/ventricles, and insertion site for myofibrils
• Collagen types: Type I predominates (80-85%), Type III provides distensibility; abnormal deposition causes restrictive cardiomyopathy and diastolic dysfunction
• Extracellular matrix: Contains proteoglycans, glycoproteins, and matricellular proteins; regulates fibroblast function and myocyte interactions

Tissue-Level Organization

• Laminar architecture: Myocytes organized in branching sheets spiraling from base to apex; creates coordinated radial, longitudinal, and circumferential contraction
• Myocyte-fibroblast interactions: Cardiac fibroblasts (comprise ~70% of cells but only 10% of mass) produce extracellular matrix and communicate via paracrine signaling; undergo transformation to myofibroblasts (increased α-SMA expression) during fibrosis

Developmental and Structural Variations

• Hypertrophic cardiomyopathy (HCM): Disorganized myocyte architecture with chaotic fiber arrangement and myocyte disarray; sarcomeric gene mutations (β-MHC, MYBPC3, tropomyosin, troponins) alter contractility
• Dilated cardiomyopathy (DCM): Myocyte dropout and replacement fibrosis; dystrophin-associated protein complex mutations (Duchenne/Becker muscular dystrophy) disrupt membrane stability
• Arrhythmogenic cardiomyopathy: Desmosomal protein mutations (desmoplakin, plakoglobin, desmoglein-2, desmocollin-2) causing intercalated disc disruption and fibrofatty infiltration

Acquired Pathologic Changes

• Myocardial infarction: Acute coagulation necrosis with neutrophil infiltration (6-24 hours); granulation tissue formation (3-14 days); collagen deposition and scar formation (weeks to months); loss of myocytes triggers compensatory hypertrophy
• Myocarditis: Inflammatory infiltrates (lymphocytes, macrophages, neutrophils) with varying myocyte damage; etiologies include viral (enterovirus, adenovirus), bacterial, autoimmune, and infiltrative diseases
• Cardiac amyloidosis: Extracellular amyloid deposition (transthyretin or light chain) between myocytes and fibroblasts; disrupts calcium handling and causes restrictive physiology

Metabolic and Storage Disorders

• Glycogen storage diseases: Pompe disease (acid maltase deficiency) accumulates glycogen in myocytes causing hypertrophic cardiomyopathy; Danon disease (LAMP2 mutation) causes lysosomal accumulation
• Fabry disease: α-galactosidase deficiency leads to globotriaosylceramide accumulation in myocytes, fibroblasts, and conducting tissue; causes HCM phenotype with conduction abnormalities

Symptoms Related to Contractile Dysfunction

• Dyspnea on exertion: Results from diastolic dysfunction and pulmonary edema; caused by reduced compliance in restrictive patterns or impaired relaxation in hypertrophic disease
• Orthopnea and paroxysmal nocturnal dyspnea: Indicates elevated pulmonary capillary wedge pressure from systolic dysfunction
• Syncope/presyncope: In HCM due to dynamic outflow tract obstruction or arrhythmias from disorganized conduction; in restrictive disease from severe diastolic dysfunction limiting cardiac output

Physical Examination Findings

• Prominent S4 gallop: Audible in hypertrophic and restrictive cardiomyopathies reflecting forceful atrial contraction into stiff ventricle; absent in pure systolic dysfunction without diastolic abnormality
• Systolic murmur: In HCM, late-systolic (increases with Valsalva and standing); in DCM, often absent or early-systolic mitral regurgitation; pulsus paradoxus suggests restrictive physiology
• Displaced point of maximal impulse: Indicates left ventricular dilation; occurs in DCM and post-infarction remodeling; located >5-6 cm lateral to midclavicular line
• Irregular pulse: Seen with atrial fibrillation (common in restrictive cardiomyopathy and amyloidosis); conducting tissue pathology predisposes to arrhythmias
• Signs of right heart failure: Elevated jugular venous pressure, hepatomegaly, peripheral edema; occur with restrictive physiology or post-infarction right ventricular involvement

Histologic Examination and Tissue Analysis

• Myocardial biopsy indications: Suspected myocarditis (presenting with acute heart failure and ventricular dysfunction), infiltrative/storage diseases, restrictive cardiomyopathy, and unexplained HCM with atypical features
• Light microscopy findings:
• HCM: myocyte disarray (>5% of sample), hypertrophied myocytes (>1.5× control), increased collagen deposition
• DCM: myocyte dropout, replacement fibrosis, variation in myocyte size
• Myocarditis: inflammatory infiltrates with myocyte necrosis/apoptosis
• Amyloidosis: Congo red-positive material with apple-green birefringence under polarized light

Immunohistochemistry and Advanced Techniques

• Immunofluorescence: Identifies desmosomal protein loss in arrhythmogenic cardiomyopathy; detects dystrophin deficiency in Duchenne muscular dystrophy
• Electron microscopy: Reveals sarcomeric disarray, mitochondrial abnormalities, storage material in metabolic disorders, and ultrastructural details of necrotic myocytes
• Genetic testing: Next-generation sequencing (NGS) panels for cardiomyopathy-associated genes; identifies mutations in sarcomeric proteins, desmosomal genes, and metabolic enzymes

Imaging Correlation with Histology

• Cardiac MRI: Identifies scar patterns (late gadolinium enhancement/LGE) correlating with necrosis and fibrosis; restrictive pattern shows subendocardial enhancement; HCM shows midwall fibrosis
• Echocardiography: Chamber dimensions, wall thickness, function; mitral regurgitation severity; septal morphology in HCM
• Electrocardiography: Voltage patterns, conduction delays; repolarization abnormalities in HCM; low voltage in amyloidosis/infiltrative disease

Laboratory and Biomarker Evaluation

• Troponin (high-sensitivity): Elevated in myocarditis, myocardial infarction, and acute decompensation; correlates with myocyte necrosis
• B-type natriuretic peptide (BNP): Elevated in systolic and diastolic heart failure; reflects chamber stretch and wall stress
• Serum/urine light chains: Evaluated in cardiac amyloidosis; identifies light chain (AL) versus transthyretin (ATTR) subtype
• Genetic screening: HFE mutations in hemochromatosis; GLA gene in Fabry disease; GAA gene in Pompe disease

Disease-Modifying Therapy Based on Underlying Pathology

• Immunosuppression: Corticosteroids (prednisone 1 mg/kg/day tapered over weeks) and azathioprine or mycophenolate mofetil for giant cell or eosinophilic myocarditis with recurrent symptoms; improves outcomes in inflammatory subtypes
• Immunoglobulin: Consider intravenous immunoglobulin (IVIG) in severe cases with fulminant presentation
• Mechanical support: Extracorporeal membrane oxygenation (ECMO) or ventricular assist devices (VADs) as bridge to recovery or transplantation

• Cardiac amyloidosis: Tafamidis (transthyretin stabilizer) slows progression in ATTR amyloidosis; inotersen (antisense oligonucleotide) or diflunisal (NSAID) reduce transthyretin production; ixazomib and bortezomib for AL amyloidosis by targeting plasma cell-produced light chains
• Fabry disease: Enzyme replacement therapy (imiglucerase or agalsidase-beta) or chaperone therapy (migalastat) reduce globotriaosylceramide accumulation; stabilizes cardiac function when initiated early
• Hemochromatosis: Phlebotomy (remove iron-loaded red blood cells) or chelation therapy (deferoxamine, deferasirox) prevent iron-mediated myocardial fibrosis and arrhythmias

Symptomatic Management and Heart Failure Therapy

• ACE inhibitors/ARBs: Lisinopril, enalapril, or losartan; inhibit renin-angiotensin-aldosterone system reducing afterload and preventing adverse remodeling
• Beta-blockers: Carvedilol, metoprolol-XL, bisoprolol; reduce heart rate, afterload, and arrhythmia burden; improve remodeling through antiadrenergic effects
• Aldosterone antagonists: Spironolactone or eplerenone; reduce fibrosis and sudden death in reduced ejection fraction; monitor potassium
• SGLT2 inhibitors: Dapagliflozin or empagliflozin; reduce hospitalizations and mortality in HFrEF through multiple mechanisms (natriuresis, improved myocyte metabolism, reduced inflammation)
• HCN inhibitors: Ivabradine for symptomatic improvement in systolic dysfunction by selective heart rate reduction

• Diuretics: Loop diuretics for volume overload; caution with excessive diuresis reducing cardiac output in restrictive patterns
• Calcium channel blockers (non-dihydropyridines): Verapamil, diltiazem improve ventricular relaxation in restrictive cardiomyopathy and HCM by reducing calcium-induced stiffness
• Beta-blockers: Slow heart rate allowing longer diastolic filling time; reduce LVOT obstruction in HCM

• Disopyramide: Negative inotrope combined with anticholinergic effects reduces dynamic LVOT obstruction and symptoms in HCM; second-line after beta-blockers/non-DHP CCBs
• Mavacamtens (cardiac myosin inhibitor): First-in-class direct myosin modulator reducing contractile force; reduces LVOT gradient and improves symptoms in symptomatic obstructive HCM
• Septal reduction therapy: Alcohol septal ablation or surgical myectomy for refractory symptoms with LVOT obstruction >50 mmHg

Arrhythmia Management

• Antiarrhythmics: Amiodarone (broad spectrum, many drug interactions) or sotalol (beta-blocker with class III properties) for atrial fibrillation and ventricular arrhythmias
• Implantable cardioverter-defibrillator (ICD): Indicated for primary prevention in HCM with high-risk features (massive LVH >30 mm, syncope, family history of sudden death) or secondary prevention after ventricular fibrillation
• Catheter ablation: For arrhythmias refractory to medical therapy; particularly effective for accessory pathways in pre-excitation

Nonpharmacologic Measures

• Lifestyle modification: Restrict intense competitive sports in HCM and inherited

Emergencies (act before the biopsy result returns)

• Ventricular fibrillation / pulseless VT: Myocyte disarray (HCM), fibrofatty replacement (arrhythmogenic cardiomyopathy), or patchy replacement fibrosis creates zones of slowed conduction and unidirectional block → reentry. Signaled by syncope during exertion or witnessed arrest; per AHA ACLS these are the shockable rhythms — immediate defibrillation, not adenosine or amiodarone first.
• Post-infarct mechanical rupture: Days 3–7 the necrotic wall is populated by macrophages digesting collagen and is at its weakest. Free-wall rupture → sudden pulseless electrical activity with tamponade; papillary muscle rupture → abrupt severe mitral regurgitation and flash pulmonary edema; septal rupture → new harsh holosystolic murmur with oxygen step-up. All require emergent echo and surgery.
• Complete heart block: Amyloid, sarcoid, Fabry, hemochromatosis, or Lyme carditis infiltrating nodal/His tissue. Bradycardia with syncope warrants temporary pacing and treatment of the underlying cause. Permanent pacing is indicated for irreversible infiltrative block (amyloid, Fabry, hemochromatosis) but is not indicated for reversible causes such as Lyme carditis, which resolves with antibiotics; in cardiac sarcoidosis with high-grade AV block the 2018 ACC/AHA/HRS guideline favors an ICD over a pacemaker.
• Fulminant giant-cell or eosinophilic myocarditis: Extensive myocyte necrosis → cardiogenic shock; mechanical circulatory support and immunosuppression.

Disease-related, subacute

• Progressive interstitial fibrosis: Type I collagen replaces lost myocytes → restrictive filling, atrial dilation, atrial fibrillation, and thromboembolism (intracardiac thrombus occurs in amyloidosis even in sinus rhythm).
• Endomyocardial biopsy risk: Right ventricular perforation with tamponade (emergency), tricuspid injury, and sampling error — patchy myocarditis yields false negatives.

Treatment-related

• Septal reduction therapy: Alcohol ablation infarcts the basal septum → RBBB, and in roughly 10% complete heart block requiring a permanent pacemaker; myectomy typically causes LBBB and rarely an iatrogenic VSD.
• Mavacamten: Excess myosin inhibition → systolic dysfunction; ejection fraction is monitored on a serial-echo REMS program.
• Disopyramide: QT prolongation and anticholinergic urinary retention.
• Amiodarone: Thyroid, hepatic, and pulmonary fibrosis toxicity.
• MRAs: Hyperkalemia; SGLT2 inhibitors: euglycemic ketoacidosis and genital mycotic infection.

• Intercalated disc trio: Gap junctions (connexin-43) provide electrical coupling, desmosomes provide mechanical adhesion, adherens junctions anchor actin. Desmosomal mutations → arrhythmogenic cardiomyopathy with fibrofatty replacement of the RV, epsilon wave, and exercise-induced VT — the single association examiners test most.
• Cardiac T-tubules sit at the Z-line and pair with one SR cistern (a dyad); skeletal muscle T-tubules sit at the A–I junction and form triads. This swap is the classic distractor.
• Myocyte disarray (whorled, chaotic fibers with interstitial fibrosis) is the histologic signature of hypertrophic cardiomyopathy; contrast with myocyte dropout and replacement fibrosis in dilated cardiomyopathy.
• **Congo red with *apple-green birefringence*** under polarized light = amyloid. When ECG shows low voltage but echo shows thick walls (voltage–mass mismatch, with apical sparing on strain), the ACC consensus pathway calls for screening for monoclonal protein — serum/urine immunofixation plus serum free light chains — obtained together with bone scintigraphy, since a positive PYP scan is diagnostic of ATTR only if monoclonal protein testing is negative.
• Purkinje fibers: large, pale, glycogen-rich, myofibril-poor subendocardial cells with the fastest conduction; the AV node is the slowest, owing to small fibers and sparse gap junctions.
• Post-MI timeline: coagulative necrosis with contraction band necrosis and neutrophils in the first days, macrophages days 3–7 (weakest wall), granulation tissue in weeks 1–3, dense collagenous scar thereafter. Cardiomyocytes are terminally differentiated — repair is scar, never regeneration.
• Buzzword bank: Aschoff bodies with Anitschkow cells = rheumatic carditis; zebra (lamellar) bodies on EM = Fabry disease; perinuclear lipofuscin = brown atrophy of aging.
• Do not reflexively give non-dihydropyridine calcium channel blockers or digoxin in suspected cardiac amyloidosis — the stiff, low-output ventricle tolerates negative inotropy and preload reduction poorly.